Expression of Constitutively Active Nuclear-κB RelA Transcription Factor in Blasts of Acute Myeloid Leukemia

Human Pathology

Volumn 35, Issue 2, 2004, Pages 246-253

  Bueso Ramos, Carlos E ^a   Rocha, Frederico C ^b   Shishodia, Shishir ^b   Medeiros, L Jeffrey ^b   Kantarjian, Hagop M ^b   Vadhan Raj, Saroj ^b   Estrov, Zeev ^b   Smith, Terry L ^b   Nguyen, Martin H ^b   Aggarwal, Bharat B ^b  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b NONE

Author keywords

Bone marrow; Leukemia; Myelodysplastic syndrome; NF B

Indexed keywords

GRANULOCYTE COLONY STIMULATING FACTOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PROTEIN BCL 2; TRANSCRIPTION FACTOR RELA;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; AGED; ARTICLE; BLAST CELL; BLAST CELL CRISIS; CANCER THERAPY; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL SURVIVAL; CHILD; CHRONIC MYELOID LEUKEMIA; CHRONIC MYELOMONOCYTIC LEUKEMIA; CONTROLLED STUDY; FEMALE; GEL MOBILITY SHIFT ASSAY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOFLUORESCENCE TEST; LEUKEMIA CELL; MAJOR CLINICAL STUDY; MALE; MYELODYSPLASTIC SYNDROME; PROTEIN EXPRESSION;

EID: 10744224210     PISSN: 00468177     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.humpath.2003.08.020     Document Type: Article

References (35)

1. Kosari CL, Ries LAG, Miller BA, et al (eds): SEER Cancer Statistics Review, 1973-1992: Tables and Graphs. Bethesda, MD, National Cancer Institute, 1995 (NIH publication no. 96-2789)
2. Sachs L: The control of hematopoiesis and leukemia: From basic biology to the clinic. Proc Natl Acad Sci USA 93:4742-4749, 1996
3. Tenen DG: Disruption of differentiation in human cancer: AML shows the way. Nat Rev Cancer 3:89-101, 2003
4. Chen F, Castranova V, Shi X, et al: New insights into the role of nuclear factor-κB, a ubiquitous transcription factor in the initiation of diseases. Clin Chem 45:7-17, 1999
5. Sonenshein GE: Rel/NF-κB transcription factors and the control of apoptosis. Semin Cancer Biol 8:113-119, 1997
6. Gilmore TD, Koedood M, Piffat KA, et al: Rel/NF-κB/IκB proteins and cancer. Oncogene 14:1367-1378, 1997
7. Baldwin AS: Control of oncogenesis and cancer therapy resistance by the transcription factor NF-κB. J Clin Invest 107:241-246, 2001
8. Garg A, Aggarwal BB: Nuclear transcription factor-κB as a target for cancer development. Leukemia 16:1053-1068, 2002
9. Pyatt DW, Stillman WS, Yang Y, et al: An essential role for NF-κB in human CD34+ bone marrow cell survival. Blood 93;3302-3308, 1999
10. Shishodia S, Aggarwal BB: Nuclear factor kB activation: A question of life or death. J Biochem Mol Biol 35:28-40, 2002
11. Karin M, Ben-Neriah Y: Phosphorylation meets ubiquitination: The control of NF-κB activity. Ann Rev Immunol 18:621-663, 2000
12. Zhang M-Y, Sun S-C, Bell L, et al: NF-κB transcription factors are involved in normal erythropoiesis. Blood 91:4136-4144, 1998
13. McDonald PP, Bald A, Cassatella MA: Activation of the NF-κB pathway by inflammatory stimuli in human neutrophils. Blood 89:3421-3433, 1997
14. Gerondakis S, Grumont R, Rourke I, et al: The regulation and roles of Rel/NF-κB transcription factors during lymphocyte activation. Curr Opin Immunol 10:353-359, 1998
15. Grumont RJ, Rourke IJ, O'Reilly LA, et al: B lymphocytes differentially use the Rel and nuclear factor kB1 (NF-κB1) transcription factors to regulate cell cycle progression and apoptosis in quiescent and mitogen-activated cells. J Exp Med 187:663-674, 1998
16. Sha WC: Regulation of immune responses by NF-κB/Rel transcription factors. J Exp Med 187:143-146, 1998
17. Lu D, Thompson JD, Gorski GK, et al: Alterations at the rel locus in human lymphoma. Oncogene 6:1235-1241, 1991
18. Neri A, Chang C-C, Lombardi L, et al: B-cell lymphoma-associated chromosomal translocation involves candidate oncogene lyt-10, homologous to NF-κB p50. Cell 67:1075-1087, 1991
19. Bargou RC, Emmerich F, Krappmann D, et al: Constitutive nuclear factor-κB-RelA activation is required for proliferation and survival of Hodgkin's disease tumor cells. J Clin Invest 100:2961-2969, 1997
20. Emmerich F, Meiser M, Hummel M, et al: Overexpression of I kappa B alpha without inhibition of NF-κβ activity and mutations in the I kappa alpha gene in Reed-Sternberg cells. Blood 94:3129-3134, 1999
21. Dokter WHA, Tuyt L, Sierdsema SJ, et al: The spontaneous expression of interleukin-1β and interleukin-6 is associated with spontaneous expression of AP-1 and NF-κB transcription factor in acute myeloblastic leukemia cells. Leukemia 9:425-432, 1995
22. Kordes U, Krappmann D, Heissmeyer V, et al: Transcription factor NF-κB is constitutively activated in acute lymphoblastic leukemia cells. Leukemia 14:399-402, 2000
23. Mori N, Fujii M, Ikeda S, et al: Constitutive activation of NF-κB in primary adult T-cell leukemia cells. Blood 93:2360-2368, 1999
24. Guzman ML, Neering SJ, Upchurch D, et al: Nuclear factor-κB is constitutively activated in primitive human acute myelogenous leukemia cells. Blood 98:2301-2307, 2001
25. Guzman ML, Swiderski CF, Howard DS, et al: Preferential induction of apoptosis for primary human leukemic stem cells. Proc Natl Acad Sci USA 99:16220-16225, 2002
26. Grimwade D, Walker H, Oliver F, et al: The importance of diagnostic cytogenetics on outcome in AML: Analysis of 1,612 patients entered into the MRC AML 10 Trial. The Medical Research Council Adult and Children's Leukemia Working Parties. Blood 92: 2322-2333, 1998
27. Jaffe ES, Harris NL, Stein H, et al (eds): World Health Organization Classification of Tumors: Pathology and Genetics of Tumors of Haematopoietic and Lymphoid Tissues. Lyon, France, IARC Press, 2001, pp 16-107
28. Chaturvedi MM, Kumar A, Darnay BG, et al: Sanguinarine (pseudochelerythrine) is a potent inhibitor of NF-κB activation, IκBα phosphorylation, and degradation. J Biol Chem 272:30129-30134, 1997
29. Rassidakis GZ, Medeiros LJ, Vassilakopoulos TP, et al: BCL-2 expression in Hodgkin and Reed-Sternberg cells of classical Hodgkin disease predicts a poorer prognosis in patients treated with ABVD or equivalent regimens. Blood 100:3935-3941, 2002
30. Dunn SM, Coles LS, Lang RK, et al: Requirement for nuclear factor (NF)-kappa B p65 and NF-interleukin-6 binding elements in the tumor necrosis factor response region of the granulocyte colony-stimulating factor promoter. Blood 83:2469-2479, 1994
31. Tsoplou P, Kouraklis-Symeonidis A, Thanopoulou E, et al: Apoptosis in patients with myelodysplastic syndromes: Differential involvement of marrow cells in "good" versus "poor" prognosis patients and correlation with apoptosis-related genes. Leukemia 13: 1554-1563, 1999
32. Turhan AG, Solary E, Vaichenker W, et al: Molecular pathophysiology of chronic myelogenous leukemia. Hematol Cell Ther 40:217-221, 1998
33. Reuther JY, Reuther GW, Cortez D, et al: A requirement for NF-κB activation in Bcr-Abl-mediated transformation. Genes Dev 12: 968-981, 1998
34. Milella M, Estrov Z, Kornblau SM, et al: Synergistic induction of apoptosis by simultaneous disruption of the Bcl-2 and MEK/MAPK pathways in acute myelogenous leukemia. Blood 99:3461-3464, 2002
35. Estrov Z, Manna SK, Harris D, et al: Phenylarsine oxide blocks interleukin-1κ-induced activation of the nuclear transcription factor NF-κB, inhibits proliferation, and induces apoptosis of acute myelogenous leukemia cells. Blood 94:2844-2853, 1999